Raju Chelluri

Dr. Raju Chelluri

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Journal of Urology
Verified
Journal Article
Open access
EKEric C. Kauffman
Eric C. Kauffman
MLMin-Jung Lee
Min-Jung Lee
SASylvia V. Alarcon
Sylvia V. Alarcon
SLSunmin Lee
Sunmin Lee
AHAnthony N. Hoang
Anthony N. Hoang
PPPeter A. Pinto
Peter A. Pinto
Purpose: While the significance of circulating tumor cells in clinically localized cancer remains controversial, it has been reported that surgical tumor manipulation can increase circulating tumor...

24 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DODavid Anthony Ostrowski
David Anthony Ostrowski
RCRaju Chelluri
Raju Chelluri
MHMatthew Herzig
Matthew Herzig
LXLeilei Xia
Leilei Xia
BCBrian Cortese
Brian Cortese
S. MalkowiczS. Malkowicz
S. Malkowicz
The ongoing Bacillus Calmette-Guérin (BCG) shortage has created challenges for the treatment of non-muscle invasive bladder cancer (NMIBCa). Our objective was to evaluate the efficacy of reduced-dose induction BCG (RD-iBCG) compared to full-dose induction BCG (FD-iBCG) regarding recurrence rates. We hypothesized that patients receiving RD-iBCG may recur at a higher rate compared to those who received FD-iBCG therapy. A retrospective review of all patients with NMIBCa treated with intravesical therapy at our institution between 2015–2020 was conducted. Inclusion criteria consisted of having a diagnosis of AUA intermediate or high-risk NMIBCa with an indication for a six-week induction course of FD or RD-BCG with at least 1 year of documented follow up. The data were censored at one year. Propensity score matching for age, sex, tumor pathology, and initial vs. recurrent disease was performed. The primary endpoint was bladder cancer recurrence, reported as recurrence-free survival. A total of 254 patients were reviewed for this study. Our final cohort was 139 patients after exclusion. Thirty-nine percent of patients had HGT1 disease. 38.6% of patients receiving RD-BCG developed a recurrence of bladder cancer within a one-year follow-up as compared to 33.7% of patients receiving FD therapy. After propensity matching, this value remained statistically significant (p = 0.03). In conclusion, RD-iBCG for NMIBCa is associated with a significantly greater risk of recurrence than full-dose induction therapy, suggesting that RD-iBCG may not be equivalent or non-inferior to full-dose administration in the short term.

24 May 2020 in Urology Case Reports
Verified
Journal Article
Open access
VOVictor Otaño-Rivera
Victor Otaño-Rivera
RCRaju Chelluri
Raju Chelluri
TGThomas J. Guzzo
Thomas J. Guzzo
AWAlan J. Wein
Alan J. Wein
PMPhillip Mucksavage
Phillip Mucksavage
Renal artery pseudoaneurysm (RAP) is a potentially life-threatening complication after partial nephrectomy (PN). Studies suggests that most cases present within 15 days post operatively with one of three classic symptoms: gross hematuria, flank pain and/or anemia. However, there are a limited number of reports in the literature regarding delayed RAP (≥four months). To the best of our knowledge we report the first case of RAP six months following robotic-assisted PN.

1 September 2020 in Urology Case Reports
Verified
Journal Article
Open access
DRDaniel Roberson
Daniel Roberson
RCRaju Chelluri
Raju Chelluri
AWAlan J. Wein
Alan J. Wein
PMPhillip Mucksavage
Phillip Mucksavage
Chylous ascites (CA) is a known complication of retroperitoneal surgery. We are reporting the case of a 65-year-old male who underwent a robotic assisted laparoscopic (RAL) partial nephrectomy for a renal mass and subsequently developed CA. He was successfully treated with a low-fat diet and maintenance of a surgical drain. To our knowledge, this is the first reported case of CA following right RAL partial nephrectomy. Current literature shows a significantly greater incidence of CA after left sided kidney surgery and with concurrent lymph node dissection. The majority of patients with this complication can be successfully managed without reoperation.

25 August 2023
Verified
Book Chapter
Closed access
RCRaju Chelluri
Raju Chelluri
RKRobert C. Kovell
Robert C. Kovell